***Background.*** Infectious pulmonary complications (IPC) cause significant morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HSCT). Diagnostic chest imaging and microbiologic testing are essential tools for evaluating IPCs in the posttransplant setting.

***Methods.*** A retrospective chart review was performed on an established cohort of 94 patients who underwent allogeneic HSCT at MSKCC between September 4, 2009 and August 4, 2011. A pulmonary complication was defined as incident clinically-relevant abnormal parenchymal findings identified on diagnostic imaging from the start of pretransplant conditioning until up to 3 years posttransplantation. An IPC was considered to be infectious (proven, probable or possible) based on the results of standard evaluation of respiratory and other specimens, as well as clinical interpretation. Relationships between transplant factors, IPC diagnoses and clinical outcomes were evaluated using logistic regression.

***Results.*** Over 3 years, 62/94 (66%) of subjects developed at least one posttransplant IPC. 55/62 (89%) occurred during the first year, of which 33 (60%) occurred during the first month after HSCT. Nearly half of subjects (33) had undergone ablative preparative conditioning. 44 (73%) of IPCs were considered bacterial, 15 (24%) viral and 3 (5%) fungal in origin. 13 (21%) diagnoses were proven, with identification of specific viral (HHV6, respiratory viruses), bacterial (Legionella, Klebsiella, Pseudomonas spp), or fungal (Aspergillus) organisms in lower respiratory tract specimens. 28 (45%) of IPC diagnoses were considered probable, and 21 (33.9%) were non-specific. Multivariate analysis demonstrated that a pulmonary complication more than doubled the risk of death from any cause \[OR 2.6 (1.1-6.9) 95% CI; p = 0.046\].

***Conclusion.*** This study demonstrates a high incidence of post-transplant IPCs at an academic transplant center. The minority carried a specific diagnosis, thereby limiting targeted intervention in the majority of cases. Importantly, pulmonary complications were associated with a significant increase in overall mortality following HSCT. Recognition and effective management of these complications are important in order to optimize overall care of these patients and their subsequent clinical outcomes.
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